|
Join us as we discuss the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Recent clinical data suggest that the absence or abundance of certain microbes may be directly linked to certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel syndrome (IBS). Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 2 development including, SYN-004 which is designed to protect the g
|
